2. Search Result
Search Result
Results for "

SV2A

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Isotope-Labeled Compounds

2

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0106
    Levetiracetam
    2 Publications Verification

    UCB L059

    		 DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent [2].
    Levetiracetam
  • HY-167830
    SDM-8

    		Radionuclide-Drug Conjugates (RDCs) Neurological Disease
    SDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease .
    SDM-8
  • HY-157999
    SDI-118

    		Synaptic Vesicle Proteins Neurological Disease
    SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC50 of 13 nM .
    SDI-118
  • HY-119810
    Seletracetam
    1 Publications Verification

    Ucb 44212

    		 Synaptic Vesicle Proteins Neurological Disease
    Seletracetam (Ucb 44212), as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy [2] .
    Seletracetam
  • HY-B0106R
    Levetiracetam (Standard)

    UCB L059 (Standard)

    		 Reference Standards DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent [2].
    Levetiracetam (Standard)
  • HY-RS16880
    Sv2a Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sv2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sv2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sv2a Mouse Pre-designed siRNA Set A
    Sv2a Mouse Pre-designed siRNA Set A
  • HY-RS14054
    SV2A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SV2A Human Pre-designed siRNA Set A contains three designed siRNAs for SV2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SV2A Human Pre-designed siRNA Set A
    SV2A Human Pre-designed siRNA Set A
  • HY-136873
    UCB-J

    		Synaptic Vesicle Proteins Neurological Disease
    UCB-J is a ligand for synaptic vesicle protein 2A (SV2A) with pIC50 values for human and rat SV2A of 8.15 and 7.6 respectively. UCB-J can be used to display and quantify the total synaptic density throughout the brain [2] .
    UCB-J
  • HY-B0106S
    Levetiracetam-d6

    UCB L059-d6

    		 Isotope-Labeled Compounds DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent [2].
    Levetiracetam-d6
  • HY-RS23322
    Sv2a Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sv2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Sv2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sv2a Rat Pre-designed siRNA Set A
    Sv2a Rat Pre-designed siRNA Set A
  • HY-119810A
    Seletracetam lithium

    Ucb 44212 lithium

    		 HIV Neurological Disease
    Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy [2] .
    Seletracetam lithium
  • HY-119810B
    Seletracetam lithium bromide

    Ucb 44212 lithium bromide

    		 Synaptic Vesicle Proteins Neurological Disease
    Seletracetam (Ucb 44212) lithium bromide, an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy [2] .
    Seletracetam lithium bromide
  • HY-176866
    Rodin-A

    		HDAC Neurological Disease
    Rodin-A is an orally active, brain-penetrant and selective histone deacetylase (HDAC)-co-repressor of repressor element-1 silencing transcription factor (CoREST) complex inhibitor with an IC50 value of 1.80 μM for the CoREST complex, 0.15 μM for HDAC1, and 0.43 μM for HDAC2. Rodin-A increases the acetylation level of histone H3K9, upregulates the expression of neuron-related genes, thereby promoting the increase in dendritic spine density, the colocalization of synaptic proteins (SV2A and PSD95), and the improvement of hippocampal long-term potentiation (LTP), exerting synaptic protection and repair activity. Rodin-A is promising for research of neurodegenerative diseases related to synaptic dysfunction, especially Alzheimer’s disease .
    Rodin-A
  • HY-B0106S1
    Levetiracetam-d3

    UCB L059-d3

    		 DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent [2].
    Levetiracetam-d3
  • HY-12772R
    Hydroxy Itraconazole (Standard)

    Itraconazole metabolite Hydroxy Itraconazole (Standard); R-63373 (Standard)

    		 Reference Standards Fungal Drug Metabolite Others
    Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent [2].
    Hydroxy Itraconazole (Standard)
  • HY-176867
    Rodin-B

    		HDAC Neurological Disease
    Rodin-B is a selective histone deacetylase (HDAC)-co-repressor of repressor element-1 silencing transcription factor (CoREST) complex inhibitor with an IC50 value of 0.50 μM for the CoREST complex, 0.27 μM for HDAC1, and 0.28 μM for HDAC2. Rodin-B increases the acetylation level of histone H3K9, upregulates the expression of neuron-related genes, thereby promoting the increase in dendritic spine density, the colocalization of synaptic proteins (SV2A and PSD95), and the improvement of hippocampal long-term potentiation (LTP), exerting synaptic protection and repair activity. Rodin-B is promising for research of neurodegenerative diseases related to synaptic dysfunction, especially Alzheimer’s disease .
    Rodin-B
  • HY-136873A
    (Rac)-UCB-J

    		Synaptic Vesicle Proteins Neurological Disease
    (Rac)-UCB-J (Compound 23) is a ligand for synaptic vesicle protein 2A (SV2A), with a pIC50 value of 8.2. (Rac)-UCB-J can be used as a PET tracer for SV2A to assist in the diagnosis of epilepsy research .
    (Rac)-UCB-J
  • HY-180554
    UCB1244283

    		Synaptic Vesicle Proteins Neurological Disease
    UCB1244283 is a synaptic vesicle glycoprotein 2A (SV2A) allosteric modulator. UCB1244283 binds to a secondary ligand-binding site in SV2A and enhances orthosteric ligand engagement when the orthosteric site is occupied, by stabilizing the occluded state and slowing ligand dissociation. UCB1244283 shows a clear protective effect against both tonic and clonic convulsions in sound-sensitive mice. UCB1244283 can be used for epilepsy research [2] .
    UCB1244283

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: